New Trial Starts for Patients with Idiopathic Pulmonary Fibrosis
Dr. Martin Kolb, Director of the Division of Respirology at the Department of Medicine at McMaster University and an expert on interstitial lung disease discusses Horizon Therapeutics‘ Phase 2b pivotal trial to evaluate HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with idiopathic pulmonary fibrosis (IPF), the most common interstitial lung disease
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Healthcare. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Healthcare and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Healthcare?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Martin Kolb is the director of the Division of Respirology at the Department of Medicine at McMaster University and an expert on interstitial lung disease. Dr. Kolb is the primary investigator for Horizon Therapeutics’ Phase 2b clinical trial for HZN-825 in idiopathic pulmonary fibrosis and runs a specialty clinic for interstitial lung diseases and pulmonary fibrosis at St. Joseph’s Healthcare. Dr. Kolb has published more than 80 scientific articles and is Deputy Editor for Respirology and on the Editorial Board of the American Journal of Respiratory and Critical Care Medicine.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
